Market Assessment, Non Small Cell Lung Cancer Unmet Need US/EU 2016 Report

Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of <5%; treatments delivering improvements to survival are therefore a key treatment goal in this disease. Despite recent approvals of Portrazza, Opdivo and Keytruda for metastatic squamous-cell NSCLC, surveyed oncologists highlight that novel therapies with improved clinical efficacy are still an area of high unmet need. This report investigates key drivers of prescribing in squamous-cell NSCLC, and identifies key areas of unmet need in the indication.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2016

Related Market Assessment Reports

Vitiligo – Executive Insights – Executive Insights (US)

Dry Eye – Access & Reimbursement – Detailed, Expanded Analysis (US)

Obesity/Overweight – Unmet Need – Detailed, Expanded Analysis (US/EU)

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis (US)

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)